• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CYP3A4酶活性低的白人个体中的CYP3A4变异等位基因。

CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity.

作者信息

García-Martín Elena, Martínez Carmen, Pizarro Rosa M, García-Gamito Francisco J, Gullsten Harriet, Raunio Hannu, Agúndez José A G

机构信息

Department of Biochemistry, School of Biological Sciences, University of Extremadura, Badajoz, Spain.

出版信息

Clin Pharmacol Ther. 2002 Mar;71(3):196-204. doi: 10.1067/mcp.2002.121371.

DOI:10.1067/mcp.2002.121371
PMID:11907494
Abstract

OBJECTIVE

Our objective was to evaluate the presence of CYP3A4 gene variants in white individuals with low CYP3A4 enzyme activity.

METHODS

Persons with extremely low enzyme activity, either in vitro or in vivo, were selected in a panel of 97 healthy subjects. Genetic analyses for CYP3A4 variant alleles present in white subjects, including CYP3A41B, CYP3A42, CYP3A44, CYP3A45, CYP3A46, CYP3A48, CYP3A411, CYP3A412, and CYP3A4*13, were performed on genomic deoxyribonucleic acid from these subjects by amplification-restriction and sequencing.

RESULTS

With the exception of CYP3A41B, none of the variant alleles analyzed were present in 30 genes from persons with extremely low enzyme activity. CYP3A41B was present in the population studied with an allele frequency of 5.5%. Nevertheless, the presence of CYP3A41B does not correlate with low enzyme activity, either in vivo or in vitro, in either heterozygosity or homozygosity. CYP3A42 was not identified in 290 genes from Spanish persons or in 70 genes from Finnish persons.

CONCLUSIONS

Although the genetic component of the interindividual variability of CYP3A4 enzyme activity seems to be high, our findings do not support a key role for the variant alleles analyzed on the majority of white persons with low CYP3A4 activity. This suggests the occurrence of as yet unknown mutations that affect CYP3A4 or other functionally related genes.

摘要

目的

我们的目的是评估细胞色素P450 3A4(CYP3A4)酶活性低的白人个体中CYP3A4基因变异的存在情况。

方法

在97名健康受试者组成的队列中选择体外或体内酶活性极低的个体。通过扩增-限制和测序对这些受试者的基因组脱氧核糖核酸进行CYP3A4变异等位基因的基因分析,这些变异等位基因存在于白人受试者中,包括CYP3A41B、CYP3A42、CYP3A44、CYP3A45、CYP3A46、CYP3A48、CYP3A411、CYP3A412和CYP3A4*13。

结果

除CYP3A41B外,酶活性极低的个体的30个基因中均未检测到所分析的其他变异等位基因。CYP3A41B在研究人群中的等位基因频率为5.5%。然而,无论杂合子还是纯合子,CYP3A41B的存在与体内或体外的低酶活性均无相关性。在290名西班牙人的基因或70名芬兰人的基因中均未鉴定出CYP3A42。

结论

虽然CYP3A4酶活性个体间变异的遗传成分似乎很高,但我们的研究结果不支持所分析的变异等位基因在大多数CYP3A4活性低的白人个体中起关键作用。这表明存在尚未知晓的影响CYP3A4或其他功能相关基因的突变。

相似文献

1
CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity.CYP3A4酶活性低的白人个体中的CYP3A4变异等位基因。
Clin Pharmacol Ther. 2002 Mar;71(3):196-204. doi: 10.1067/mcp.2002.121371.
2
Common allelic variants of cytochrome P4503A4 and their prevalence in different populations.细胞色素P4503A4的常见等位基因变体及其在不同人群中的患病率。
Pharmacogenetics. 2002 Mar;12(2):121-32. doi: 10.1097/00008571-200203000-00006.
3
CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity.外显子7和12中具有氨基酸替换的CYP3A4等位基因变体:催化活性改变的等位基因变体的证据。
Clin Pharmacol Ther. 2000 Jan;67(1):48-56. doi: 10.1067/mcp.2000.104391.
4
Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan.右美沙芬表型分析测定细胞色素P450活性时缺乏性别差异和较大的个体内变异性。
J Clin Pharmacol. 2001 Jul;41(7):723-31. doi: 10.1177/00912700122010627.
5
Novel mutations of CYP3A4 in Chinese.中国人中CYP3A4的新型突变
Drug Metab Dispos. 2001 Mar;29(3):268-73.
6
Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes.三种主要人类肝脏细胞色素P450同工酶催化活性和免疫反应性的个体间差异。
Eur J Clin Pharmacol. 1996;51(1):79-85. doi: 10.1007/s002280050164.
7
Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.用右美沙芬N-去甲基化法测定体内细胞色素P450 3A4/5活性。
Clin Pharmacol Ther. 1996 Oct;60(4):374-84. doi: 10.1016/S0009-9236(96)90194-0.
8
Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region.CYP3A4肝脏表达的个体差异:与5'-上游调控区基因多态性的关系。
Biochem Biophys Res Commun. 1999 May 27;259(1):201-5. doi: 10.1006/bbrc.1999.0752.
9
Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
J Natl Cancer Inst. 1999 Sep 15;91(18):1587-90. doi: 10.1093/jnci/91.18.1587.
10
Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.CYP3A4和CYP3A5的共同调节及其对肝脏和肠道中咪达唑仑代谢的作用。
Mol Pharmacol. 2002 Jul;62(1):162-72. doi: 10.1124/mol.62.1.162.

引用本文的文献

1
CYP3A4 and CYP3A5: the crucial roles in clinical drug metabolism and the significant implications of genetic polymorphisms.细胞色素P450 3A4和细胞色素P450 3A5:在临床药物代谢中的关键作用及基因多态性的重要意义
PeerJ. 2024 Dec 5;12:e18636. doi: 10.7717/peerj.18636. eCollection 2024.
2
The influence of drug-induced metabolic enzyme activity inhibition and CYP3A4 gene polymorphism on aumolertinib metabolism.药物诱导的代谢酶活性抑制和CYP3A4基因多态性对奥莫替尼代谢的影响。
Front Pharmacol. 2024 May 24;15:1392849. doi: 10.3389/fphar.2024.1392849. eCollection 2024.
3
Pharmacokinetics, Pharmacodynamics, and Side Effects of Midazolam: A Review and Case Example.
咪达唑仑的药代动力学、药效学及副作用:综述与病例示例
Pharmaceuticals (Basel). 2024 Apr 8;17(4):473. doi: 10.3390/ph17040473.
4
influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantation.影响异基因造血干细胞移植后口服他克莫司的药代动力学及急性肾损伤发生时间。
Front Pharmacol. 2024 Jan 8;14:1334440. doi: 10.3389/fphar.2023.1334440. eCollection 2023.
5
Genotyping in Clinical Practice: Ready for Implementation?临床实践中的基因分型:准备好实施了吗?
Front Genet. 2021 Jul 8;12:711943. doi: 10.3389/fgene.2021.711943. eCollection 2021.
6
Physiologically-Based Pharmacokinetic-Pharmacodynamics Model Characterizing CYP2C19 Polymorphisms to Predict Clopidogrel Pharmacokinetics and Its Anti-Platelet Aggregation Effect Following Oral Administration to Coronary Artery Disease Patients With or Without Diabetes.基于生理的药代动力学-药效学模型,该模型表征CYP2C19基因多态性,以预测口服给药后氯吡格雷在合并或不合并糖尿病的冠心病患者中的药代动力学及其抗血小板聚集作用。
Front Pharmacol. 2020 Dec 17;11:593982. doi: 10.3389/fphar.2020.593982. eCollection 2020.
7
Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targeting CYP3A4*1G allele function.美国印第安人和阿拉斯加原住民社区 CYP3A 遗传药理学变异的特征分析,针对 CYP3A4*1G 等位基因功能。
Clin Transl Sci. 2021 Jul;14(4):1292-1302. doi: 10.1111/cts.12970. Epub 2021 Jan 27.
8
Impact of Drug-Gene-Interaction, Drug-Drug-Interaction, and Drug-Drug-Gene-Interaction on (es)Citalopram Therapy: The PharmLines Initiative.药物-基因相互作用、药物-药物相互作用以及药物-药物-基因相互作用对艾司西酞普兰治疗的影响:PharmLines计划
J Pers Med. 2020 Nov 28;10(4):256. doi: 10.3390/jpm10040256.
9
Failure of Achieving Tacrolimus Target Blood Concentration Might Be Avoided by a Wide Genotyping of Transplanted Patients: Evidence from a Retrospective Study.通过对移植患者进行广泛基因分型可避免他克莫司目标血药浓度未达标的情况:一项回顾性研究的证据
J Pers Med. 2020 Jun 1;10(2):47. doi: 10.3390/jpm10020047.
10
Representation of CYP3A4, CYP3A5 and UGT1A4 Polymorphisms within Croatian Breast Cancer Patients' Population.在克罗地亚乳腺癌患者群体中 CYP3A4、CYP3A5 和 UGT1A4 多态性的表达。
Int J Environ Res Public Health. 2020 May 23;17(10):3692. doi: 10.3390/ijerph17103692.